Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

Share Price is delayed by 15 minutes
Get Live Data
395.00    -1.00 (-0.25%)
Bid:
390.00
Ask:
400.00
Spread: 10.00 (2.564%)
Market Cap: £189.59m
TSTL Live PriceLast checked at - London Stock Exchange

Intraday Tristel Share Chart

EPA approval received

23 Apr 2018 07:00

RNS Number : 6996L
Tristel PLC
23 April 2018
 

 

Tristel plc

("Tristel" or "the Company")

 

EPA approval received

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that the United States Environmental Protection Agency ("EPA") has registered its foam-based chlorine dioxide product, Duo. This registration enables Tristel to market Duo to clean and disinfect hard, non-porous surfaces. The federal registration will be followed by state-by-state approvals which the Company expects to complete by the end of 2018. The Company anticipates first revenues from the United States during its 2018-19 financial year.

 

Paul Swinney, CEO of Tristel plc, comments: "We have achieved our first United States regulatory approval, and we will continue to pursue further registrations with the EPA and the Food and Drug Administration ("FDA") to build a broadly-based business in the USA.

 

"We recently announced that we have appointed Parker Laboratories Inc to manufacture Duo in its FDA approved facility in New Jersey, and to sell Duo into the ultrasound marketplace in which they have national sales coverage. We will sell our products through different channels into other clinical areas in the USA hospital market.

 

"This first United States approval is a very significant step for our Company as it enables us to access the largest healthcare market in the world. It has been our long-held ambition to be recognised as a global brand in the infection prevention industry. An active presence in the United States is necessary to achieve this ambition, and now we can build upon the foundation stone laid in our collaboration with Parker to progress confidently towards our goal."

 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

Liz Dixon, Finance Director

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

finnCap

Tel: 020 7220 0500

Geoff Nash/ Giles Rolls (Corporate Finance)

Alice Lane (Corporate Broking)

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFKBDNQBKDPQB
Date   Source Headline
5th Apr 20222:45 pmRNSDirector/PDMR Shareholding
29th Mar 20223:40 pmRNSDirector/PDMR Shareholding
23rd Feb 20224:45 pmRNSInterim dividend confirmation
22nd Feb 202211:30 amRNSDirector/PDMR Shareholding
21st Feb 20224:40 pmRNSSecond Price Monitoring Extn
21st Feb 20224:35 pmRNSPrice Monitoring Extension
21st Feb 20227:00 amRNSHalf-year Report
17th Feb 20223:00 pmRNSIssue of Equity
1st Feb 20227:00 amRNSConfirmation of Interim Results
13th Dec 20215:13 pmRNSResult of AGM
13th Dec 20217:00 amRNSAGM Statement and notice of results
27th Oct 20217:00 amRNSDirector/PDMR Shareholding
21st Oct 20214:39 pmRNSDirector/PDMR Shareholding
19th Oct 20215:35 pmRNSHolding(s) in Company
18th Oct 20213:50 pmRNSIssue of Equity
18th Oct 202111:59 amRNSDirector/PDMR Shareholding
18th Oct 20217:00 amRNSFinal Results
12th Oct 20215:58 pmRNSHolding(s) in Company
22nd Sep 20217:00 amRNSNotice of Results
23rd Aug 20217:00 amRNSIssue of Equity
10th Aug 20217:00 amRNSIssue of Equity
29th Jul 20216:29 pmRNSTR1: Notification of Major Holdings
21st Jul 20217:00 amRNSTrading update
9th Jul 20211:21 pmRNSIssue of Equity
24th Jun 20217:00 amRNSRegulatory approval for EPA, Canada & South Korea
8th Jun 20217:00 amRNSIssue of Equity
13th May 20213:30 pmRNSIssue of Equity
26th Apr 20213:15 pmRNSDirector/PDMR Shareholding
26th Apr 20212:06 pmRNSSecond Price Monitoring Extn
26th Apr 20212:00 pmRNSPrice Monitoring Extension
26th Apr 202111:05 amRNSSecond Price Monitoring Extn
26th Apr 202111:00 amRNSPrice Monitoring Extension
26th Apr 20217:00 amRNSTrading Update
21st Apr 20213:00 pmRNSIssue of Equity
19th Apr 20211:00 pmRNSIssue of Equity
6th Apr 20211:00 pmRNSDirector/PDMR Shareholding
1st Apr 20217:00 amRNSTotal Voting Rights
26th Mar 202110:40 amRNSIssue of Equity
4th Mar 20217:00 amRNSDirector/PDMR Shareholding
1st Mar 20215:00 pmRNSDirector/PDMR Shareholding and Issue of Equity
22nd Feb 20217:00 amRNSHalf-year Report
18th Feb 202111:15 amRNSNotice of investor presentation
15th Feb 202111:00 amRNSIssue of Equity
29th Jan 20217:00 amRNSIssue of Equity
14th Jan 20212:00 pmRNSExercise of Options
24th Dec 20207:00 amRNSDirector Appointment
15th Dec 202011:39 amRNSResult of AGM
15th Dec 20207:00 amRNSAGM Statement and notice of results
2nd Dec 20202:00 pmRNSUpdate to Executive Performance Share Plan 2021
2nd Dec 202010:30 amRNSTristel wins AIM Growth Business of the Year Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.